Aurobindo Pharma has inked a pact to acquire select commercial products in France from Teva for an undisclosed amount.
Arrow Generiques SAS, the French subsidiary of the company "will acquire the right, title and interest in products Calcium and Calcium Vitamin D3, including the use of the Orocal trademark from Teva", Aurobindo Pharma said in a BSE filing.
The two companies intend to ensure continuity of the supply of the products to the market, it added.
Following the receipt of clearances from European authorities, Arrow Generiques will integrate these products with its existing commercial operations in France, Aurobindo Pharma said.
"This acquisition will enable Arrow Generiques to continue to increase its branded products portfolio and leverage its position as a key player in the drug market," it added.
Shares of Aurobindo Pharma closed 4.07 per cent up at Rs 739.90 on BSE.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
